7th November 2016
Innovative biotechnology company, Axim Biotechnologies Inc has appointed Grayling in the US to support its Investor Relations and Public Relations’ needs.
Axim Biotechnologies is engaged in the research and development, and production of pharmaceutical, nutriceutical and cosmetic products, as well as the procurement of genetically and nano-controlled active ingredients. The company’s particular focus is on the development of treatments for pain, spasticity, anxiety and other medical disorders using cannabinoids-based products. Pharmaceutical R&D aims to deliver systems and active pharmaceutical ingredients for treating conditions such as Parkinson's disease, Alzheimer's disease, restless leg syndrome and Crohn's disease.
Presently, the company is conducting clinical studies of MedChewRx, a pharmaceutical chewing gum containing cannabinoids. The company is in the process of getting FDA and EMA regulatory approval to launch this product in 2017, and it is in regard to this that Grayling is providing support.
Grayling’s efforts will be driven by New York based executive vice president, Lucia Domville. She says: “This is a fascinating company that is really pushing the boundaries with its research, and we are thrilled to be their partner.”
18th May 2016
After 4.5 years at Grayling, Swedish MD Kristian Hultqvist has decided to leave the company for a senior position at JKL/MSL Group.Danjell Elgebrandt has taken over as Managing Director. Mr Elgebrandt...Read More
20th April 2016
Grayling has been shortlisted for six SABRE Awards, in recognition of work across the EMEA region. The shortlisted campaigns are:#WhereverYouAre - our campaign for PayPal in Russia, which has also...Read More
11th March 2016
Tågoperatören MTR Express utmanar SJ på sträckan Stockholm till Göteborg. De senaste månaderna har bolaget drivit en intensiv kampanj för att berätta varför det är det bästa alternativet...Read More